No Data
US Stock MarketDetailed Quotes
BIIB Biogen
Watchlist
300.200
-2.210-0.73% Close 06/02 16:00 ET
300.750+0.550+0.18%
Post 18:05 ET
303.170High297.680Low817.15KVolume
302.530Open302.410Pre Close245.43MTurnover0.57%Turnover Ratio13.98P/E (TTM)43.45BMarket Cap319.74052wk High14.38P/E (Static)144.74MShares188.53552wk Low3.15P/B43.33BFloat Cap480.180Historical High--Dividend TTM144.32MShs Float2.625Historical Low--Div YieldTTM1.82%Amplitude300.348Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
TYSABRI--2.03B19.96%
SPINRAZA--1.79B17.63%
Revenues from anti-CD20 therapeutic programs--1.7B16.72%
TECFIDERA--1.44B14.19%
AVONEX--973.5M9.57%
VUMERITY--553.4M5.44%
Other revenues--485.1M4.77%
BENEPALI--441M4.33%
other--419.7M4.13%
PLEGRIDY--331.9M3.26%
View all
News
Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Acadia Healthcare (ACHC)
Biogen Price Target Maintained With a $340.00/Share by RBC Capital
Biogen Price Target Maintained With a $340.00/Share by RBC Capital
Research Alert: CFRA Maintains Hold Opinion On Shares Of Biogen Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target by $25 to $314, 18.7x
Comments
ColumnsToday's Pre-Market Stock Movers: SBUX, AMD, PACW, LLY and More
Gapping up
$Pearson(PSO.US$ +8% (Pearson shares popped more than 8%. The stock was double upgraded to buy from underperform by Bank of America, which said Tuesday's sell-off in the stock, which followed a sharp decline in Chegg amid AI worries, was "overly harsh.")
$Generac(GNRC.US$ +6% (The energy technology company gained 6.5% after quarterly earnings beat analyst expectations. Generac reported an adjusted 63 cents per share again...
$Pearson(PSO.US$ +8% (Pearson shares popped more than 8%. The stock was double upgraded to buy from underperform by Bank of America, which said Tuesday's sell-off in the stock, which followed a sharp decline in Chegg amid AI worries, was "overly harsh.")
$Generac(GNRC.US$ +6% (The energy technology company gained 6.5% after quarterly earnings beat analyst expectations. Generac reported an adjusted 63 cents per share again...
12
1
2
Read more